

K081793

1/2

510(k) Summary

OCT 14 2008

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92.

1. The submitter of this premarket notification is:

Markus Stacha
 Philips Medizin Systeme Boeblingen GmbH
 Hewlett-Packard-Str. 2
 D-71034 Boeblingen, Germany
 Tel: ++49 7031 463-2840, Fax: ++49 7031 463-2442
 e-mail: markus.stacha@philips.com

This summary was prepared on June 23, 2008.

2. The names of the devices are: Philips MP5 and MP5T IntelliVue Patient Monitors and Philips TRx4841A IntelliVue Telemetry System Transceiver.
 Classification names are as follows:

Device Panel	Classification	ProCode	Description
Cardiovascular Devices	§870.1025, II	DSI	Detector and alarm, arrhythmia
	§870.1025, II	MLD	Monitor, ST Segment with Alarm
	§870.1025, II	MHX	Monitor, Physiological, Patient (with arrhythmia detection or alarms)
	§870.1435, II	DXG	Computer, Diagnostic, Pre-Programmed, Single-Function
	§870.2060, II	DRQ	Amplifier and Signal Conditioner, Transducer Signal
	§870.2300, II	DRT	Monitor, Cardiac (incl. Cardiotachometer & Rate Alarm)
	§870.2340, II	DPS	Electrocardiograph
	§870.2340, II	MLC	Monitor, ST Segment
	§870.2350, II	DRW	Electrocardiograph, Lead Switching Adapter
	§870.2370, II	KRC	Tester, Electrode, Surface, Electrocardiograph
	§870.2600, I	DRJ	System, Signal Isolation
	§870.2700, II	DQA	Oximeter
	§870.2800, II	DSH	Recorder, Magnetic tape, Medical
	§870.2810, I	DSF	Recorder, Paper Chart
	§870.2900, I	DSA	Cable, Transducer and Electrode, incl. Patient Connector
	-	MSX	System, Network and Communication, Physiological Monitors
	§870.2910, II	DRG	Transmitters and Receivers, Physiological Signal, Radiofrequency
Anesthesiology Devices	§868.2375, II	BZQ	Monitor, Breathing Frequency

3. The modified devices are substantially equivalent to previously cleared Philips MP5 and MP5T IntelliVue Patient Monitors and the Philips TRx4841A IntelliVue Telemetry System Transceiver marketed pursuant to K062392, K063725, K040357, and K041741.
4. The modification is a change that adds wireless connection between the Philips MP5 and MP5T IntelliVue Patient Monitors and the Philips TRx4841A IntelliVue Telemetry System Transceiver as an alternative to the existing cable connection.
5. The modified devices have the same intended use as the legally marketed predicate devices.
They are intended for the monitoring, recording, and alarming of multiple physiological parameters of adults and pediatrics in hospital environments and during transport inside hospitals.
6. The modified devices have the same technological characteristics as the legally marketed predicate devices.
7. Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the modified devices with respect to the predicates. Testing involved system level tests, safety, EMC, performance, environmental and functionality tests. Pass/Fail criteria were based on the specifications cleared for the predicate devices and test results showed substantial equivalence. The results successfully demonstrate that the Philips MP5 and MP5T IntelliVue Patient Monitors with Philips TRx4841A IntelliVue Telemetry System Transceiver meet all reliability requirements and performance claims.



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

OCT 14

Philips Medizin Systeme Boeblingen GmbH
Cardiac and Monitoring Systems
c/o Mr. Egon Pfeil
Regulatory Affairs Engineer
Hewlett-Packard-Str. 2, D-71034
Boeblingen, Germany

Re: K081793
Trade/Device Name: Philips MP5 and MP5T IntelliVue Patient Monitors, and Philips
TRx4841A IntelliVue Telemetry System Transceiver
Regulation Number: 21 CFR 870.1025
Regulation Name: Arrhythmia Detector and Alarm (Including ST-Segment Measurement
and Alarm)
Regulatory Class: Class II (Two)
Product Code: MHX
Dated: September 12, 2008
Received: September 15, 2008

Dear Mr. Stacha:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometrics' (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Bram D. Zuckerman", is written over the typed name.

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K081793

Device Name:

Philips MP5 and MP5T IntelliVue Patient Monitors and Philips
TRx4841A IntelliVue Telemetry System Transceiver.

Indications for Use:


Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients. Intended for monitoring and recording of, and to generate alarms for, multiple physiological parameters of adults and pediatrics in hospital environments and during transport inside hospitals.

Prescription Use yes AND/OR
(Part 21 CFR 801 Subpart D)

Over-The-Counter Use No
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
OF NEEDED)

Concurrence of CDRM, Office of Device Evaluation (ODE)


(Division Sign-Off) 12/14/08
Division of Cardiovascular Devices

510(k) Number K081793